CJC-1295 with DAC
Modified growth hormone releasing hormone (GHRH) analog with Drug Affinity Complex. DAC binds albumin, extending half-life to approximately 8 days. Produces sustained GH elevation via continuous pituitary stimulation rather than pulsatile release. Raises baseline IGF-1 steadily over weeks.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- igf-1
- fasting-glucose
- fasting-insulin
- hba1c
- active-cancer
- diabetes-uncontrolled
- pituitary-tumor
- PMID:16352683Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone — J Clin Endocrinol Metab, 2006
- PMID:16595757CJC-1295, a long-acting GHRH analog: repeated subcutaneous administration — J Clin Endocrinol Metab, 2006
CJC-1295 with DAC is the set-it-and-forget-it GH peptide. One injection per week. Steady-state IGF-1 elevation. The tradeoff is that you lose pulsatile GH release — the natural spike-and-valley pattern your pituitary uses. Some researchers argue the pulsatile pattern matters for tissue specificity. The DAC version gives you convenience at the cost of physiological fidelity. The no-DAC version preserves the pulse. Different tools for different frameworks.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See CJC-1295 with DAC in a protocol matched to you